Chimerix (NASDAQ:CMRX) is up 10% premarket on light volume in reaction to preclinical data
that, it says, support the rationale of using brincidofovir to treat
smallpox (and stockpiling as a countermeasure in the event of an
outbreak). The results were presented at the ASM Biothreats Conference
in Arlington, VA.
In two lethal animal models of smallpox, treatment
with brincidofovir resulted in a statistically significant survival
advantage compared to placebo.
The company plans to file a U.S. marketing application mid-year.
https://seekingalpha.com/news/3535683-chimerix-up-10-premarket-on-potential-of-brincidofovir-in-smallpox
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.